key: cord-0827810-58j40ksu
authors: Rice, Shauna M.; Ferree, Sarah D.; Atanaskova Mesinkovska, Natasha; Shadi Kourosh, Arianne
title: The Art of Prevention: COVID-19 Vaccine Preparedness for the Dermatologist
date: 2021-01-12
journal: Int J Womens Dermatol
DOI: 10.1016/j.ijwd.2021.01.007
sha: dd004303c85f740527bc52a4484332f2b54aa561
doc_id: 827810
cord_uid: 58j40ksu

As COVID-19 vaccinations begin, dermatologists must be aware of the cutaneous adverse events reported in the clinical trials, including injection site and hypersensitivity reactions, and emerging evidence of dermal filler injection reactions following vaccination. The filler reaction may represent development of a delayed-type hypersensitivity in the setting of another immunologic trigger, i.e. the vaccine. Upon literature review of similar reactions, their pathophysiology and management, we present a set of timely clinical considerations for counseling, prevention and management of the possible cutaneous sequelae of the COVID-19 vaccine, and encourage documentation of vaccine-related reactions to aid the safety-data collection in the Vaccine Adverse Event Reporting System and the American Academy of Dermatology COVID-19 Registry.

Abstract: As COVID-19 vaccinations begin, dermatologists must be aware of the cutaneous adverse events reported in the clinical trials, including injection site and hypersensitivity reactions, and emerging evidence of dermal filler injection reactions following vaccination. The filler reaction may represent development of a delayed-type hypersensitivity in the setting of another immunologic trigger, i.e. the vaccine. Upon literature review of similar reactions, their pathophysiology and management, we present a set of timely clinical considerations for counseling, prevention and management of the possible cutaneous sequelae of the COVID-19 vaccine, and encourage documentation of vaccine-related reactions to aid the safety-data collection in the Vaccine Adverse Event Reporting System and the American Academy of Dermatology COVID-19 Registry.

As physicians, our role of stewardship in promoting public health guidelines and vaccination is clear, while remaining prepared to prevent and manage the possible effects in the skin. From the COVID-19 vaccine trial data available, we present an overview of the current cutaneous reactions reported with analysis of similar reactions from the literature to guide a dermatologist's considerations for vaccine-related counseling, prevention and management.

As seen with other vaccines, cutaneous reactions following COVID-19 vaccine have included localized redness and swelling (Figure 1 ) among the mild adverse reactions in all reaching phase 3 trials (Table 1) . Thus far, other skin reactions have been reported with the Moderna vaccine, e.g. injection site reactions, injection site urticaria, and "maculo-papular rash" (Table 2 ) (Food and Drug Administration (FDA), 2020). Suspected allergic reactions to polyethylene glycol (PEG), a known excipient in the vaccines, suggest care be taken in those who are patch test positive or with history of allergy to PEG-containing products (penicillin, laxatives, makeup, injected corticosteroids, antacids, chemotherapy drugs, certain fillers) (Garvey and Nasser, 2020; Damiano Monticelli et al, 2019) .

The FDA brief on the Moderna vaccine also reported reactions to dermal filler following vaccination in three patients in the experimental arm of the trial. Two of these patients had facial swelling, one reporting filler injection 6 months prior and the other 2 weeks prior to vaccination;

in the third patient who had lip swelling only, timing of the last filler injection was unknown and a similar reaction occurred following an influenza vaccine in the past ( Figure 2 ) (Zhang, 2020; FDA, 2020) . All reactions resolved. Two patients in the placebo group of this trial also reported facial swelling, indicating other possible triggers apart from the vaccine or filler could have confounded the cases in the experimental vaccine group. To our knowledge, no similar reactions have yet been reported with the Pfizer BNT162b2 mRNA or other COVID-19 vaccines (Polack et al, 2020) ; however the information available is evolving and the estimation of risk and prevalence of a vaccine-filler cross reactivity is limited as the types of filler used in the patients with reactions was not reported, and query of history of filler injection is not part of routine screening; thus, the true number of patients with a history of filler injections who have already received the vaccine without reactions is yet unknown.

Immunogenic dermal filler reactions are rare, with both immediate and delayed type hypersensitivity reactions (DTR) reported and a global incidence rate of 0.8% for hyaluronic acid (HA) fillers (Beleznay et al, 2015) . Immediate hypersensitivity reactions, within minutes of injection, occur via immunoglobulin E-mediated histamine release from mast cells and manifest as urticaria, angioedema, and anaphylaxis. While DTRs (incidence of 0.42%), mediated by macrophage and T-cell interactions, typically develop 48-72 hours after injection, they can also occur weeks to months afterward with swelling and erythema at the filler site (Lowe et al, 2001) or with granuloma formation at the site months or even years after (Alijotas-Reig et al, 2013).

Among the existing theories for why DTRs are seen with dermal filler after certain immunogenic triggers (e.g. COVID-19 or other vaccines) is that fillers may act as adjuvants rather than direct T-cell activators, enhancing the antigen-specific immune response without triggering one on their own. Thus, in genetically predisposed individuals, there is a lower threshold for vaccines, infections, or other inciting factors to trigger inflammatory reactions (Alijotas-Reig et al, 2018).

A recent report showed higher risk of DTRs to filler in patients with HLA subtypes B*08 and DRB1*03, with linkage to a predisposition for autoimmune and/or granulomatous disorders (Decates et al, 2020) . Abnormalities in acute phase reactants, C-reactive protein, fibrinogen, and low complement levels may also play a role, possibly through an autoimmune mechanism (Alijotas-Reig and Garcia-Gimenez, 2008). Additionally, HA begins to degrade 3-5 months postinjection, which may lead to breakdown products and exposure to unknown antigens that can stimulate the immune system when paired with additional triggers (Beleznay et al, 2015) .

Certain predisposing factors may cause susceptibility to HA filler DTRs, including injury, dental procedures, medications, and illnesses (e.g. facial erythema and edema following influenza-like illness (Beleznay et al, 2015; Turkmani et al, 2019) ). Two reports document swelling and nodules in the setting of an acute sinusitis, 2-4 months after last HA filler injection (Humphrey et al, 2020) . Pathmanathan et al describe a case of DTR to HA progressing over the course of 48 hours following chemotherapy with cetuximab (an epidermal growth factor receptor inhibitor), with the patient developing cheek nodules and edema at areas injected with filler 6 months prior (2019). In addition to HA, permanent fillers such as polymethylmethacrylate (PMMA) have also caused immunogenic reactions in susceptible individuals, with granuloma formation reported after viral infections or facial injury (Fischer et al, 2007; Lemperle et al, 2003) . Even in those with no known history of immunologic risk factors, facial edema and nodule formation has occurred in the setting of respiratory infection 3 weeks after filler injection, suggesting that the window for immunogenic triggers can be at least 3 weeks (Homsy et al, 2017) .

Cutaneous reactions to the COVID-19 vaccine in clinical trials, though few at this early stage, may signal dermatologic sequelae to come as larger segments of the world's population become vaccinated. Questions may arise as patients hear of potential reactions raising suspicion against vaccination or see skin reactions in themselves or others. Dermatologists must be informed and prepared to address these situations as they arise, assisting our patients through the vaccination process at this critical juncture for public health in our society.

In caring for certain groups, pre-vaccine counseling may become especially relevant. For example, patients with allergies, history of injection site reactions or urticaria may benefit from instructions and management with antihistamines and topical medications. Cosmetic patients may now benefit from a discussion of COVID-19 vaccine related planning, along with screening for dental procedures and HSV, as a part of pre-procedure counseling for dermal fillers. As cutaneous implications of both COVID-19 infection and vaccine emerge, it is possible such discussions will become part of standard medical counseling prior to aesthetic procedures.

Patients seeking filler injection may be counseled regarding vaccine options not associated with adverse reactions, and especially for patients with risk factors discussed, procedures could be planned with a time window to minimize risk of reactions. While the data may be rapidly evolving, given what is known at this time, providers may consider a 4-8-week window between filler injections and vaccination for the general population, and potentially longer for those with risk factors: autoimmune or immunologic disorders, chemotherapy or immunomodulatory medications, and those with a history of sensitivity to dermal fillers (i.e. pronounced and delayed swelling as compared to expected for a given filler).

In cases of facial swelling, studies have shown resolution with short courses of oral steroids (less than 2 weeks) which do not appear to alter effectiveness of vaccines, and if necessary, hyaluronidase for residual or prolonged edema (Turkmani et al, 2019; Beleznay et al, 2015; Pathmanathan et al, 2019) . Patients should be counseled to contact their physicians for treatment if facial swelling or nodules develop, or present to the emergency room if more serious reactions occur. Additionally, although the specific fillers used by the patients in the COVID-19 vaccination trial were not reported, prior studies suggest fillers containing HA and PMMA may be more likely to cause reactions. If a patient is considering a multi-modal plan to rejuvenation, other filler options such as calcium hydroxyapatite, poly-L-lactic acid, or laser resurfacing may be prioritized especially during the months surrounding vaccinations. Dilution of filler is another reasonable consideration, with evidence showing dilution of both PLLA and HA with saline, sterile water, or lidocaine can reduce risk of adverse events and DTRs (Lowe et al, 2005; Lambros, 2011) .

With the development of novel drugs and vaccines, much of our knowledge of side effects, especially rare ones, is discovered after they come to market and are implemented in the population at magnitudes much larger than the clinical trial. Even a few cases in a clinical trial can foreshadow a phenomenon that may become a more common reaction in the larger population and should not be neglected, especially with estimates of over 2.6 million visits for filler injections annually in the U.S. alone and demand continuing even during the pandemic (ASPS 2018; Rice et al, 2020) . It must be emphasized that the risks of the vaccine are far outweighed by the benefits of the vaccine in preventing potentially deadly illness, and dermatologists should work to encourage vaccination and dispel misconceptions. We encourage physicians to document any adverse vaccine-related reactions and report them to the Vaccine Adverse Event Reporting System (https://vaers.hhs.gov/index.html), as this will aid in the ongoing safety-data collection for all COVID-19 vaccinations. Additionally, we recommend reporting cutaneous reactions to any COVID-19 vaccine to the American Academy of Dermatology COVID-19 Registry (https://www.aad.org/member/practice/coronavirus/registry), to aid the efforts of our dermatology community to better understand the specific implications of the vaccine in the skin and serve our patients. -Ramasamy, Maheshi N., et al. "Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial." The Lancet 396.10267 (2020): 1979-1993. 

Plastic Surgery Statistics

Autoimmune/inflammatory syndrome induced by adjuvants-ASIA-related to biomaterials: analysis of 45 cases and comprehensive review of the literature

Late-onset inflammatory adverse reactions related to soft tissue filler injections

Delayed immune-mediated adverse effects related to hyaluronic acid and acrylic hydrogel dermal fillers: clinical findings, long-term follow-up and review of the literature

Delayed-onset nodules secondary to a smooth cohesive 20 mg/mL hyaluronic acid filler: cause and management

Chemical characterization of hydrogels crosslinked with polyethylene glycol for soft tissue augmentation

Increased risk of late-onset, immune-mediated, adverse reactions related to dermal fillers in patients bearing HLA-B* 08 and DRB1* 03 haplotypes

Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration

Cosmetic permanent fillers for soft tissue augmentation: a new contraindication for interferon therapies

Allergic reactions to the first COVID-19 vaccine: is polyethylene glycol (PEG) the culprit?

Immunological reaction after facial hyaluronic acid injection

Retrospective review of delayed adverse events secondary to treatment with a smooth, cohesive 20-mg/mL hyaluronic acid filler in 4500 patients

A technique for filling the temples with highly diluted hyaluronic acid: the "dilution solution

Soft tissue augmentation with Artecoll: 10-year history, indications, techniques, and complications

Hyaluronic acid skin fillers: adverse reactions and skin testing

Adverse reactions to dermal fillers

Cetuximab associated dermal filler reaction

Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine

A pandemic of dysmorphia:"Zooming" into the perception of our appearance

Delayed hypersensitivity reaction to hyaluronic acid dermal filler following influenza-like illness

FDA Presentation and Voting Questions